Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study

被引:3
|
作者
Kalatharan, Vinusha [1 ]
Welk, Blayne [1 ,2 ]
Nash, Danielle M. [1 ,2 ]
Dixon, Stephanie N. [1 ,2 ]
Slater, Justin [2 ]
Pei, York [3 ]
Sarma, Sisira [1 ,2 ]
Garg, Amit X. [1 ,2 ,4 ]
机构
[1] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[2] ICES, London, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[4] Western Univ, Dept Med, Div Nephrol, London, ON, Canada
基金
加拿大健康研究院;
关键词
administrative data; autosomal dominant polycystic kidney disease; epidemiology; kidney stones; population health research; IDENTIFYING PATIENTS; PROGRESSION; EPIDEMIOLOGY; VALIDITY;
D O I
10.1177/20543581211000227
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: There is a perception that patients with autosomal dominant polycystic kidney disease (ADPKD) are more likely to develop kidney stones than the general population. Objective: To compare the rate of hospital encounter with kidney stones and the rate of stone interventions between patients with and without ADPKD. Design: Retrospective cohort study. Setting: Ontario, Canada. Patients: Patients with and without ADPKD who had a prior hospital encounter between 2002 and 2016. Measurements: Rate of hospital encounter with kidney stones and rate of stone intervention. Methods: We used inverse probability exposure weighting based on propensity scores to balance baseline indicators of health between patients with and without ADPKD. We followed each patient until death, emigration, outcomes, or March 31, 2017. We used a Cox proportional hazards model to compare event rates between the two groups. Results: Patients with ADPKD were at higher risk of hospital encounter with stones compared with patients without ADPKD (81 patients of 2094 with ADPKD [3.8%] vs 60 patients of 1902 without ADPKD [3.2%]; 8.9 vs 5.1 events per 1000 person-years; hazard ratio 1.6 [95% CI, 1.3-2.1]). ADPKD was not associated with a higher risk of stone intervention (49 of 2094 [2.3%] vs 47 of 1902 [2.4%]; 5.3 vs 3.9 events per 1000 person-years; hazard ratio 1.2 [95% CI = 0.9-1.3]). Limitations: We did not have information on kidney stone events outside of the hospital. There is a possibility of residual confounding. Conclusion: ADPKD was a significant risk factor for hospital encounters with kidney stones.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Complications in Patients With Autosomal Dominant Polycystic Kidney Disease Undergoing Ureteroscopy: A Cohort Study
    Kalatharan, Vinusha
    Welk, Blayne
    Nash, Danielle M.
    McArthur, Eric
    Slater, Justin
    Sarma, Sisira
    Pei, York
    Garg, Amit X.
    CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE, 2020, 7
  • [2] Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study
    Nowak, Kristen L.
    Chonchol, Michel
    You, Zhiying
    Gupta, Malika
    Gitomer, Berenice
    CLINICAL NEPHROLOGY, 2018, 89 (03) : 196 - 204
  • [3] Kidney Stones Account for Increased Imaging Studies in Autosomal Dominant Polycystic Kidney Disease
    Simmons, Kathryn E.
    Ullman, Lawrence S.
    Dahl, Neera K.
    KIDNEY360, 2024, 5 (05): : 707 - 714
  • [4] Kidney volume and function in autosomal dominant polycystic kidney disease
    Higashihara, Eiji
    Nutahara, Kikuo
    Okegawa, Takatsugu
    Shishido, Toshihide
    Tanbo, Mitsuhiro
    Kobayasi, Kuninori
    Nitadori, Toshiaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (01) : 157 - 165
  • [5] Autophagy and Autosomal Dominant Polycystic Kidney Disease
    Oto, Ozgur Akin
    Edelstein, Charles L.
    TURKISH JOURNAL OF NEPHROLOGY, 2023, 32 (01): : 8 - 15
  • [6] Autosomal dominant polycystic kidney disease in children
    Cadnapaphornchai, Melissa A.
    CURRENT OPINION IN PEDIATRICS, 2015, 27 (02) : 193 - 200
  • [7] Autosomal dominant polycystic kidney disease in Colombia
    Camargo, Jessica T. T.
    Gonzalez, Camilo A.
    Herrera, Lina
    Yomayusa-Gonzalez, Nancy
    Ibanez, Milciades
    Valbuena-Garcia, Ana M. M.
    Acuna-Merchan, Lizbeth
    BMC NEPHROLOGY, 2023, 24 (01)
  • [8] Treatment of autosomal dominant polycystic kidney disease
    Torra, Roser
    MEDICINA CLINICA, 2014, 142 (02): : 73 - 79
  • [9] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [10] Autosomal dominant polycystic kidney disease
    Chow, Chern Li
    Ong, Albert C. M.
    CLINICAL MEDICINE, 2009, 9 (03) : 278 - 283